Powerful Tools for the Detection of Drug-Induced Toxicity to the Liver and Heart

The newly launched MaxDiscovery™ Aspartate Transaminase (AST) and Lactate Dehydrogenase (LDH) Color Endpoint Assays from Bioo Scientific are powerful tools for the detection of drug-induced toxicity to the liver and heart and can be used for preclinical testing in the drug discovery process. Both assays also have innovative technology for visible detection of in vivo toxicity using only 5 µL of serum from rodents or other mammals.

These novel assays employ simplified endpoint analysis to offer high sensitivity, low detection limits and the ability to use a visible plate reader. The MaxDiscovery™ Aspartate Transaminase (AST) kit permits quantitative visible determination of AST in a convenient format. Unlike previous LDH tests, the MaxDiscovery™ LDH Color Endpoint Assay kit measures the direct chemical conversion of LDH and does not rely on coupled enzymatic amplification for high precision, quantitative measurements.

Each kit contains ready-to-use product standards for the development of standard curves and accurate calibration of the assay. “Liver toxicity is the largest cause of attrition among new drugs under development. Our new AST and LDH kits will provide researchers with powerful tools to identify toxic effects and adjust therapeutic formulations to minimize toxicity” says Dr. Joe Krebs, Director of Protein Chemistry at Bioo. The MaxDiscovery™ Aspartate Transaminase (AST) and Lactate Dehydrogenase (LDH) Color Endpoint Assays are the latest addition to Bioo Scientific’s extensive MaxDiscovery™ line of toxicity assay kits.